Abstracts Archive - Page 2222 of 2607 - ACR Meeting Abstracts

Abstract Number: 165 • 2014 ACR/ARHP Annual Meeting
Prevalence of Gout in the Adult Population of France in 2013
Thomas Bardin¹, Pierre Clerson², Stéphane Bouée³, Gerard H. Chales⁴, Michael Doherty⁵, René-Marc Flipo⁶, Charles Lambert⁷, Frédéric Lioté⁸, Thierry Poireaud⁹, Thierry Schaeverbeke¹⁰ and Pascal Richette¹¹, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Orgametrie, Roubaix, France, ³Cemka, Bourg la Reine, France, ⁴Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ⁵Division of Rheumatology, Orthopedics and Dermatology, University of Nottingham, Nottingham, United Kingdom, ⁶rheumatology, Rene Salengro hospital, Lille, France, ⁷Ipsen, Boulogne Billancourt, France, ⁸Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁹Menarini, Rungis, France, ¹⁰Rheumatology, Bordeaux University Hospital, Bordeaux, France, ¹¹INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France
Background/Purpose The prevalence of gout has been studied in several Western countries by various methods to approach gout diagnosis, and has been estimated to vary…
Abstract Number: 164 • 2014 ACR/ARHP Annual Meeting
Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat
Thomas Bardin¹, René-Marc Flipo², Pascal Richette³ and Pierre Clerson⁴, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²rheumatology, Rene Salengro hospital, Lille, France, ³INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France, ⁴Orgametrie, Roubaix, France
Background/Purpose Allopurinol is the standard drug for urate-lowering management of gout. Allopurinol is safe in most patients. The most frequent side effects are minor cutaneous…
Abstract Number: 163 • 2014 ACR/ARHP Annual Meeting
Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat
Thomas Bardin¹, Gérard Chales², Tristan Pascart³, René-Marc Flipo⁴, Jean-Claude Roujeau⁵, Aurélie Delayen⁶ and Pierre Clerson⁷, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ³Rheumatology, Saint-Philibert Hospital, LOMME, France, ⁴rheumatology, Rene Salengro hospital, Lille, France, ⁵Dermatology, University Paris Est, Créteil, France, ⁶Orgamétrie biostatistiques, Roubaix, France, ⁷Orgametrie, Roubaix, France
Background/Purpose: Allopurinol can lead to skin toxicity. Minor skin reactions are reported in 2-4% of patients and life threatening severe cutaneous reactions (SCARs) in 0.1-0.4%.…
Abstract Number: 162 • 2014 ACR/ARHP Annual Meeting
Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises
Hugh de Lautour¹, Nicola Dalbeth² and William Taylor³, ¹Rheumatology, Auckland District Health Broad, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Rehabilitation Teaching & Research Unit, University of Otago, Wellington, New Zealand
Background/Purpose There are currently no agreed remission criteria for gout. The aim of this study was to establish consensus for elements of potential remission criteria…
Abstract Number: 161 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Measurement of Renal and Carotid Artery Resistive Indices and Diastolic Function of the Heart in Gout Patients
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³, Rasho Rashkov¹ and Zlatimir Kolarov¹, ¹University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²University Hospital "Alexandrovska", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria
Background/Purpose Our aim was to assess the impact of gout on kidneys, diastolic function of the heart and carotid arteries. We examined ultrasonographic parameters that…
Abstract Number: 160 • 2014 ACR/ARHP Annual Meeting
All Men with Gout Should be Screened for Erectile Dysfunction
Naomi Schlesinger¹, Diane C. Radvanski² and John Kostis³, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose Erectile dysfunction (ED) is common in the general population. The likelihood of ED increases progressively with age; however, it is not an inevitable consequence…
Abstract Number: 159 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up
Naomi Schlesinger¹, Rieke Alten², Thomas Bardin³, H. Ralph Schumacher Jr.⁴, Mark Bloch⁵, Karine Lheritier⁶, Dominik Richard⁶, Andrea Stancati⁷ and Alexander So⁸, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Charité University Medicine, Berlin, Germany, ³Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ⁴University of Pennsylvania VA Medical Center, Philadelphia, PA, ⁵Holdsworth House Medical Practice, Sydney, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Campus Forum 1, Novartis Pharma AG, Basel, Switzerland, ⁸Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
Background/Purpose Frequently flaring acute gouty arthritis (GA) patients (pts), in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective, need effective alternative treatments.1 Canakinumab…
Abstract Number: 157 • 2014 ACR/ARHP Annual Meeting
Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis
Pascal Zufferey, Roxana Valcov, Isabelle Fabreguet, Alexandre Dumusc and Alexander So, DAL, RHU/CHUV, Lausanne, Switzerland
Background/Purpose The gold standard for the diagnosis of acute MSU induced arthritis is crystal identification by microscopy after joint aspiration. Alternative diagnostic tools that have…
Abstract Number: 176 • 2014 ACR/ARHP Annual Meeting
Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both
Svetlana Krasnokutsky¹, Robert T. Keenan², Laura Schneck¹, Craig Tenner³, Helene Strauss⁴, Daria Crittenden⁵, Aaron Lehmann¹ and Michael H. Pillinger¹, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²Rheumatology, Duke University, Durham, NC, ³Medicine, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Amgen, Thousand Oaks, CA
Background/Purpose: Gout is associated with increased CV risk, both dependent on, and independent of traditional CV risk factors. Recent studies suggest that OA, traditionally considered non-inflammatory,…
Abstract Number: 174 • 2014 ACR/ARHP Annual Meeting
Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study
P Sunkureddi¹, E Tóth², J. P Brown³, R Moericke⁴, D. Richard⁵, K Lheritier⁵, A Stancati⁵ and A Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gouty arthritis (GA) patients who experience frequent flares and have comorbidities have limited treatment options. Canakinumab (CAN), a selective, human, anti-interleukin1β monoclonal antibody, has…
Abstract Number: 173 • 2014 ACR/ARHP Annual Meeting
Self-Management Education for Patients with Gout: A Review of Existing Resources
Megan Johnston¹, Gareth Treharne², Peter T. Chapman³ and Lisa K. Stamp⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Psychology, University of Otago, Dunedin, New Zealand, ³Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ⁴Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose Inadequate patient self-management education resources may contribute to poor management and outcomes for gout. Patient education resources need to be easy to read and…
Abstract Number: 172 • 2014 ACR/ARHP Annual Meeting
Sleep Apnea and Risk of Incident Gout: A Population-Based Body-Mass Index Matched Cohort Study
Yuqing Zhang¹, Christine Peloquin², Maureen Dubreuil³, Edward Roddy⁴, Na Lu¹, Tuhina Neogi¹ and Hyon K. Choi⁵, ¹Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Sleep apnea is common among obese individuals with comorbidities (up to ~30%), a typical profile of gout patients. Since hypoxia associated with sleep apnea…
Abstract Number: 175 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12-Week Data
P Sunkureddi¹, E Tóth², J. P Brown³, A Kivitz⁴, A Stancati⁵, D. Richard⁵, K. Lheritier⁵ and R Moericke⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Québec, QC, Canada, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany
Background/Purpose: Chronic kidney disease (CKD) limits the treatment options in acute gouty arthritis (GA) patients due to intolerance and contraindications to available therapies. Efficacy and…
Abstract Number: 158 • 2014 ACR/ARHP Annual Meeting
Performance of Joint Ultrasonography in the Diagnosis of Suspected Acute Crystal Arthritis : Results of a Prospective Study of 112 Patients
Pascal Zufferey¹, Isabelle Fabreguet¹, Roxana Valcov¹, Alexandre Dumusc¹ and Alexander K. So Sr.², ¹DAL, RHU/CHUV, Lausanne, Switzerland, ²Dal/Rhu, CHUV, Lausanne, Switzerland
Background/Purpose The gold standard for diagnosing gout and CCP arthritis is the identification of monosodium urate (MSU) crystals in joint fluid. Ultrasound (US) features of…
Abstract Number: 151 • 2014 ACR/ARHP Annual Meeting
Sonographic Measurements Can be Misleading for Diagnosing Carpal Tunel Syndrome in Patients with Rheumatoid Arthritis
Ilker Yagci¹, Merve Akdeniz Leblebicier², Basak Mansiz Kaplan³, Demet Ozturk Gokbakan² and Gulseren Akyuz⁴, ¹Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey, ²Physical Medicine and Rehabilitation, Marmara School of Medicine, Istanbul, Turkey, ³Marmara School of Medicine, Istanbul, Turkey, ⁴Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: To compare the nerve cross sectional areas (CSA) in patients with RA without any sign of peripheral neuropathy to healthy controls.Methods: The study group was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].